Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Lowers PT on Insulet Corporation Ahead of 4Q12 Results

Share:
Related PODD
Stocks Hitting 52-Week Lows
Thursday's After-Hours Movers: NutriSystem, LinkedIn And More
Insulet (PODD) Patrick J. Sullivan on Q1 2015 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Friday, Canaccord Genuity reiterated its Buy rating on Insulet Corporation (NASDAQ: PODD), but slightly lowered its price target from $29.00 to $28.00.

Canaccord Genuity noted, “We are fine-tuning our model heading into the Q4/12 results to account for the expected impact of competitive bidding on Insulet's Neighborhood Diabetes (NDI) supplies business. Specifically, given management's commentary about the expected impact on its Medicare business, we have conservatively removed all revenues that could be impacted by competitive bidding from our estimates.”

Insulet Corporation closed on Thursday at $21.18.

Latest Ratings for PODD

DateFirmActionFromTo
May 2015Canaccord GenuityMaintainsHold
Feb 2015OppenheimerDowngradesOutperformPerform
Feb 2015JefferiesMaintainsBuy

View More Analyst Ratings for PODD
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (PODD)

Around the Web, We're Loving...